Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Asymmetric Addition. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN107188874A reveals efficient Cu-catalyzed Michael addition. High ee, mild conditions for pharma intermediates.
Patent CN110483316B reveals a safe, in-situ ketene route for high-purity L-carnitine. Discover cost-effective manufacturing and scalable supply chain solutions.
Patent CN114349585A details a copper-catalyzed asymmetric synthesis of chiral alpha-deuterated pyrrolidines using D2O, offering cost reduction in pharmaceutical intermediate manufacturing.
Patent CN110054553B details a novel chiral tetrabenzocyclooctatetraene-catalyzed method for high-purity ketone intermediates, offering significant cost and supply chain advantages.
Patent CN103373948A details a high-yield 6-step asymmetric synthesis of (-)-Kainic Acid using Rh-catalysis, offering a reliable alternative to natural extraction for neuroscience research.
Patent CN105348044B details a green synthetic route for (S)-Virol A. Offers high ee value and scalable process for pharmaceutical and agrochemical research applications.
Patent CN119613463A reveals a copper-catalyzed route for high-purity R-musk ketone, offering significant cost reduction and supply chain reliability for fragrance manufacturers.
Patent CN1218463A details novel asymmetric synthesis routes for elastase inhibitor intermediates, offering improved stereoselectivity and scalable manufacturing processes for pharmaceutical supply chains.
Novel chiral squaramide catalyzed route for Ruxolitinib intermediate. High yield, >98% ee. Cost-effective scale-up for pharma supply chains.
Patent CN108147973B details a novel thiourea-catalyzed route for ECPPA, offering superior stereoselectivity and simplified processing for ACE inhibitor manufacturing.
Patent CN117384177A reveals efficient Cu-catalyzed synthesis. Offers cost reduction and high purity for pharmaceutical intermediate manufacturing supply chains.
Patent CN105693725A reveals efficient asymmetric cycloaddition for high-purity nucleoside analogues, offering supply chain stability and cost reduction in API manufacturing.
Novel patent CN118184524A details high-yield asymmetric synthesis of Elacestrant intermediate, offering cost reduction and supply chain reliability for API manufacturing.
Novel patent CN118184524A offers 71.1% yield for Elacestrant Intermediate 5. Asymmetric synthesis eliminates chiral resolution, ensuring cost reduction and supply reliability for pharmaceutical intermediates.
Patent CN1182125C details a robust route for (2R,2-alpha-R,3a)-2-[1-(3,5-bis(trifluoromethyl)phenyl)ethoxy]-3-(4-fluorophenyl)-1,4-oxazine, offering superior yield and purity for pharmaceutical supply chains.
Patent CN102167689B details a low-cost, scalable route for chiral warfarin using amine catalysis, offering significant supply chain advantages for anticoagulant manufacturing.
Patent CN112430228B details a novel Rh-catalyzed route for chiral 2,3-dihydrobenzo[b]thiophene 1,1-dioxide, offering superior stereoselectivity and scalable manufacturing for API intermediates.
Patent CN102093166B details a scalable asymmetric synthesis of (S)-trans-1-yn-4-en-eicosan-3-ol with >97% ee, offering a reliable alternative to natural extraction for pharmaceutical applications.
Patent CN106478539A details copper-catalyzed asymmetric synthesis offering high enantioselectivity and scalable pharmaceutical intermediate production capabilities for global supply chains.
Patent CN115073399A reveals a low-cost bifunctional catalyst for high-yield chiral beta-butyrolactone production, offering significant supply chain advantages.